Poseida Therapeutics, Inc. financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 07 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 282% % -38%
Debt-to-equity 236% % 121%
Return On Equity -72% % 17%
Return On Assets -22% % 49%
Operating Margin -41% % 85%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97,465,024 shares 1.9%
Common Stock, Shares, Outstanding 97,411,571 shares 1.9%
Common Stock, Value, Issued $10,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 97,160,467 shares 5.7%
Weighted Average Number of Shares Outstanding, Diluted 98,219,947 shares 6.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $150,858,000 USD 203%
Research and Development Expense $172,428,000 USD 16%
General and Administrative Expense $40,932,000 USD 7.9%
Operating Income (Loss) $62,502,000 USD 54%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $20,278,000 USD
Income Tax Expense (Benefit) $43,000 USD -60%
Net Income (Loss) Attributable to Parent $60,759,000 USD 54%
Earnings Per Share, Basic -1 USD/shares 53%
Earnings Per Share, Diluted -1 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $49,340,000 USD 93%
Cash, Cash Equivalents, and Short-term Investments $230,900,000 USD -3.3%
Accounts Receivable, after Allowance for Credit Loss, Current $14,749,000 USD 70%
Assets, Current $250,704,000 USD -0.78%
Property, Plant and Equipment, Net $17,366,000 USD -15%
Operating Lease, Right-of-Use Asset $19,054,000 USD -16%
Intangible Assets, Net (Excluding Goodwill) $1,320,000 USD 0%
Goodwill $4,228,000 USD 0%
Other Assets, Noncurrent $905,000 USD -17%
Assets $293,577,000 USD -2.9%
Accounts Payable, Current $5,197,000 USD 104%
Employee-related Liabilities, Current $9,320,000 USD 8%
Liabilities, Current $78,269,000 USD 1.7%
Operating Lease, Liability, Noncurrent $17,734,000 USD -19%
Other Liabilities, Noncurrent $3,053,000 USD 23%
Liabilities $206,366,000 USD 16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $376,000 USD
Retained Earnings (Accumulated Deficit) $629,701,000 USD -11%
Stockholders' Equity Attributable to Parent $87,211,000 USD -29%
Liabilities and Equity $293,577,000 USD -2.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $15,135,000 USD 60%
Net Cash Provided by (Used in) Financing Activities $43,000 USD -104%
Net Cash Provided by (Used in) Investing Activities $24,003,000 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 97,411,571 shares 1.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,825,000 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $2,013,000 USD 10%
Operating Lease, Liability $23,819,000 USD -14%
Payments to Acquire Property, Plant, and Equipment $130,000 USD -83%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $60,183,000 USD 54%
Lessee, Operating Lease, Liability, to be Paid $29,304,000 USD -17%
Property, Plant and Equipment, Gross $40,218,000 USD 5.8%
Operating Lease, Liability, Current $6,085,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,107,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,374,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,485,000 USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,260,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,418,000 USD 3%
Operating Lease, Payments $1,500,000 USD -12%
Share-based Payment Arrangement, Expense $23,034,000 USD 1.8%
Interest Expense $9,073,000 USD -21%